Is dasatinib suitable for long-term use?

Dasatinib, as a targeted drug for the treatment of chronic myelogenous leukemia, whether its long-term use is appropriate is a complex issue that needs to be considered from multiple aspects.

Dasatinib is mainly used to treat patients with chronic myelogenous leukemia in the chronic phase. The duration of use varies from person to person, but is usually between 1-3 years. For many patients, the drug can be used long-term to control the condition. However, the prerequisite for long-term use is that the drug can effectively control the disease and the patient does not experience serious adverse reactions.

Long-term use of dasatinib may cause a series of adverse effects. These adverse reactions include, but are not limited to, cytopenias, hypertension, cardiac function impairment, nervous system toxicity, etc. For example, dasatinib may cause pancytopenia, which increases the risk of infection, bleeding, or anemia. In addition, drugs may also cause an increase in calcium ion concentration in myocardial cells, leading to arrhythmias and other problems. These adverse reactions may develop gradually or worsen with long-term use and require close monitoring.

Long-term use of dasatinib may also face problems with drug interactions and drug resistance. Concomitant use of dasatinib with other drugs may affect their absorption, distribution, metabolism, or excretion, thereby reducing drug efficacy. At the same time, as the medication time prolongs, tumor cells may become resistant to the drug, resulting in a decrease in therapeutic effect.

During use of dasatinib, especially in the setting of long-term use, patients should have regular monitoring of hematological parameters and assessment of cardiovascular risk. These monitoring can help detect and deal with possible adverse reactions in a timely manner. At the same time, based on the patient's response and tolerance, the doctor may adjust the drug dosage or change the treatment plan to ensure the therapeutic effect and patient safety.